For termination of section by section 4005(a) of Puspan. L. 117–180, see Effective and Termination Dates note set out below.

2022—Subsec. (a). Puspan. L. 117–180, § 4003(a)(1), substituted “fiscal year 2023” for “fiscal year 2018” in introductory provisions.

Subsec. (a)(1)(A)(iv)(I), (v)(II). Puspan. L. 117–180, § 4003(a)(2), substituted “7 days” for “5 days”.

Subsec. (a)(1)(B)(i). Puspan. L. 117–180, § 4003(a)(3)(A), inserted before period at end “, except that, in the case that such product (including, where applicable, ownership of the relevant investigational new drug application) is transferred to a licensee, assignee, or successor of such person, and written notice of such transfer is provided to the Secretary, such licensee, assignee, or successor shall pay the annual biosimilar biological product development fee”.

Subsec. (a)(1)(B)(iii)(III). Puspan. L. 117–180, § 4003(a)(3)(B), added subcl. (III).

Subsec. (a)(1)(B)(iv). Puspan. L. 117–180, § 4003(a)(3)(C), substituted “is subsequently accepted for filing” for “is accepted for filing on or after October 1 of such fiscal year”.

Subsec. (a)(1)(D). Puspan. L. 117–180, § 4003(a)(4), amended subpar. (D) generally. Prior to amendment, subpar. (D) related to payment of a reactivation fee for resuming participation in the biosimilar biological product development program and application of annual biosimilar biological product development fee for a person paying a reactivation fee.

Subsec. (a)(1)(E)(v). Puspan. L. 117–180, § 4003(a)(5), added cl. (v).

Subsec. (a)(2)(D). Puspan. L. 117–180, § 4003(a)(6), inserted “prior to approval” after “or was withdrawn”.

Subsec. (a)(3)(A)(ii), (iii). Puspan. L. 117–180, § 4003(a)(7)(A), added cl. (ii) and redesignated former cl. (ii) as (iii).

Subsec. (a)(3)(E). Puspan. L. 117–180, § 4003(a)(7)(B), added subpar. (E).

Subsec. (a)(4). Puspan. L. 117–180, § 4003(a)(8), struck out par. (4) which related to the annual fee for each biosimilar biological product in a biosimilar biological product application.

Subsec. (span)(1). Puspan. L. 117–180, § 4003(span)(2), (3), redesignated par. (2) as (1) and amended it generally. Prior to amendment, par. related to fee revenue amounts for fiscal years 2019 through 2022. Former par. (1) struck out.

Puspan. L. 117–180, § 4003(span)(1), struck out par. (1) which related to fee revenue amounts for fiscal year 2018.

Subsec. (span)(2). Puspan. L. 117–180, § 4003(span)(2), (4)(A), redesignated par. (3) as (2) and struck out “; limitations on fee amounts” after “among fees” in heading. Former par. (2) redesignated (1).

Subsec. (span)(2)(B) to (D). Puspan. L. 117–180, § 4003(span)(4)(B), (C), redesignated subpars. (C) and (D) as (B) and (C), respectively, and struck out former subpar. (B). Prior to amendment, text of subpar. (B) read as follows: “Until the first fiscal year for which the capacity planning adjustment under subsection (c)(2) is effective, the amount of any fee under subsection (a) for a fiscal year after fiscal year 2018 shall not exceed 125 percent of the amount of such fee for fiscal year 2018.”

Subsec. (span)(3), (4). Puspan. L. 117–180, § 4003(span)(2), (5), redesignated par. (4) as (3) and amended it generally. Prior to amendment, text read as follows: “For purposes of paragraph (2), the dollar amount of the annual base revenue for a fiscal year shall be the dollar amount of the total revenue amount for the previous fiscal year, excluding any adjustments to such revenue amount under subsection (c)(3).” Former par. (3) redesignated (2).

Subsec. (c)(1)(A). Puspan. L. 117–180, § 4003(c)(1)(A)(i), substituted “subsection (span)(1)(B)” for “subsection (span)(2)(B)” in introductory provisions.

Subsec. (c)(1)(A)(i). Puspan. L. 117–180, § 4003(c)(1)(A)(ii), substituted “subsection (span)(1)(A)” for “subsection (span)”.

Subsec. (c)(1)(B)(ii). Puspan. L. 117–180, § 4003(c)(1)(B), substituted “Washington-Arlington-Alexandria, DC–VA–MD–WV” for “Washington-Baltimore, DC–MD–VA–WV”.

Subsec. (c)(2) to (4). Puspan. L. 117–180, § 4003(c)(2), added pars. (2) to (4) and struck out former pars. (2) to (4) which related to application and methodology of capacity planning adjustment, operating reserve adjustment, and fiscal year 2018 adjustment, respectively.

Subsec. (c)(5). Puspan. L. 117–180, § 4003(c)(3), substituted “2023” for “2018” in introductory provisions.

Subsec. (f)(2)(B)(i). Puspan. L. 117–328, § 3625(span)(1), substituted “available—” for “available for a fiscal year beginning after fiscal year 2012”, designated remainder of existing provisions as subcl. (I), inserted “for fiscal year 2023,” before “to defray the costs”, substituted “such fiscal year; and” for “the fiscal year involved.”, and added subcl. (II).

Subsec. (f)(2)(C). Puspan. L. 117–328, § 3625(span)(2), substituted “subparagraph (B)(i) in any fiscal year if the costs allocated as described in subclause (I) or (II) of such subparagraph, as applicable,” for “subparagraph (B) in any fiscal year if the costs described in such subparagraph”.

Subsec. (f)(3). Puspan. L. 117–180, § 4003(d), substituted “2023 through 2027” for “2018 through 2022”.

Subsec. (h). Puspan. L. 117–180, § 4003(e), amended subsec. (h) generally. Prior to amendment, text read as follows: “To qualify for consideration for a waiver under subsection (d), or for a refund of any fee collected in accordance with subsection (a)(2)(A), a person shall submit to the Secretary a written request for such waiver or refund not later than 180 days after such fee is due.”

2020—Subsec. (f)(2)(B). Puspan. L. 116–136, § 3856(span)(1), amended Puspan. L. 115–52, § 905(span)(4). See 2017 Amendment note below.

2017—Subsec. (a). Puspan. L. 115–52, § 403(a)(1), substituted “fiscal year 2018” for “fiscal year 2013” in introductory provisions.

Subsec. (a)(1). Puspan. L. 115–52, § 403(a)(2), substituted “Biosimilar biological product” for “Biosimilar” in heading.

Subsec. (a)(1)(A)(i). Puspan. L. 115–52, § 403(a)(3), substituted “(c)(5)” for “(span)(1)(A)”.

Subsec. (a)(1)(B)(i). Puspan. L. 115–52, § 403(a)(4), substituted “(c)(5) for the biosimilar biological product development program” for “(span)(1)(B) for biosimilar biological product development”.

Subsec. (a)(1)(B)(ii). Puspan. L. 115–52, § 403(a)(5), substituted “annual biosimilar biological product development fee” for “annual biosimilar biological product development program fee” in introductory provisions.

Subsec. (a)(1)(B)(iii). Puspan. L. 115–52, § 403(a)(6), substituted “annual biosimilar biological product development fee” for “annual biosimilar development program fee”.

Subsec. (a)(1)(B)(iv). Puspan. L. 115–52, § 403(a)(7), added cl. (iv).

Subsec. (a)(1)(C). Puspan. L. 115–52, § 403(a)(8), substituted “for a product, effective October 1 of a fiscal year, by,” for “for a product effective October 1 of a fiscal year by,” in introductory provisions.

Subsec. (a)(1)(D)(i). Puspan. L. 115–52, § 403(a)(9)(A), inserted “, if the person seeks to resume participation in such program,” before “pay a fee” in introductory provisions.

Subsec. (a)(1)(D)(i)(I). Puspan. L. 115–52, § 403(a)(9)(B), inserted “by such person” after “grants a request”.

Subsec. (a)(1)(D)(i)(II). Puspan. L. 115–52, § 403(a)(9)(C), inserted “by such person” after “discontinued)”.

Subsec. (a)(1)(E). Puspan. L. 115–52, § 403(a)(10), struck out “biosimilar development program” after “pay” in heading.

Subsec. (a)(1)(F). Puspan. L. 115–52, § 403(a)(11)(A), struck out “biosimilar development program” after “regarding” in heading.

Subsec. (a)(1)(F)(i). Puspan. L. 115–52, § 403(a)(11)(B), amended cl. (i) generally. Prior to amendment, text read as follows: “The Secretary shall not refund any initial or annual biosimilar biological product development fee paid under subparagraph (A) or (B), or any reactivation fee paid under subparagraph (D).”

Subsec. (a)(2). Puspan. L. 115–52, § 403(a)(12)(A), struck out “and supplement” after “application” in heading.

Subsec. (a)(2)(A), (B). Puspan. L. 115–52, § 403(a)(12)(B), amended subpars. (A) and (B) generally. Prior to amendment, subpars. (A) and (B) related to the fee for a biosimilar biological product application or a supplement submitted on or after Oct. 1, 2012, and to a reduction in certain fees, respectively.

Subsec. (a)(2)(C). Puspan. L. 115–52, § 403(a)(12)(D), struck out “or supplement” after “application”.

Subsec. (a)(2)(D). Puspan. L. 115–52, § 403(a)(12)(C)–(E), in heading, struck out “or supplement” after “application” and in text, substituted “application was submitted” for “application or supplement was submitted”, “application, was accepted” for “application or supplement, was accepted”, and “application for the same product” for “application or a supplement for the same product”.

Subsec. (a)(2)(E). Puspan. L. 115–52, § 403(a)(12)(D), struck out “or supplement” after “application”.

Subsec. (a)(2)(F). Puspan. L. 115–52, § 403(c)(2), substituted “subsection (d)” for “subsection (c)”.

Puspan. L. 115–52, § 403(a)(12)(D), struck out “or supplement” after “application”.

Subsec. (a)(3). Puspan. L. 115–52, § 403(a)(13), amended par. (3) generally. Prior to amendment, par. (3) consisted of subpars. (A) to (E) which related to biosimilar biological product establishment fee, assessment, due date, assessment and division of fee for a biosimilar biological product establishment that manufactures for multiple applicants, and exception for new products, respectively.

Subsec. (a)(4)(A). Puspan. L. 115–52, § 403(c)(3), substituted “subsection (c)(5)” for “subsection (span)(1)(F)”.

Subsec. (span). Puspan. L. 115–52, § 403(span), amended subsec. (span) generally. Prior to amendment, subsec. (span) consisted of pars. (1) and (2) which related to fee amounts and limit to total amount of fees, respectively.

Subsec. (c). Puspan. L. 115–52, § 403(c)(4), added subsec. (c). Former subsec. (c) redesignated (d).

Subsec. (d). Puspan. L. 115–52, § 403(c)(1), redesignated subsec. (c) as (d). Former subsec. (d) redesignated (e).

Subsec. (d)(1). Puspan. L. 115–52, § 403(d), substituted “affiliate shall pay” for “affiliate shall pay—” and “not a small business.” for “not a small business; and”, struck out subpar. (A) designation before “application fees for all”, and struck out subpar. (B) which read as follows: “all supplement fees for all supplements to biosimilar biological product applications submitted to the Secretary for review in the same manner as an entity that is not a small business.”

Subsec. (e). Puspan. L. 115–52, § 403(e), substituted “all such fees” for “all fees”.

Puspan. L. 115–52, § 403(c)(1), redesignated subsec. (d) as (e). Former subsec. (e) redesignated (f).

Subsec. (f). Puspan. L. 115–52, § 403(c)(1), redesignated subsec. (e) as (f). Former subsec. (f) redesignated (g).

Subsec. (f)(2)(B). Puspan. L. 115–52, § 905(span)(4), as amended by Puspan. L. 116–136, § 3856(span)(1), substituted “limitations” for “limitation” in heading, designated existing provisions as cl. (i) and inserted heading, and added cl. (ii).

Subsec. (f)(2)(C). Puspan. L. 115–52, § 403(f)(1)(A), added subpar. (C) and struck out former subpar. (C). Prior to amendment, text read as follows: “Until the date of enactment of an Act making appropriations through September 30, 2013, for the salaries and expenses account of the Food and Drug Administration, fees authorized by this section for fiscal year 2013 may be collected and shall be credited to such account and remain available until expended.”

Subsec. (f)(2)(D). Puspan. L. 115–52, § 403(f)(1)(B), struck out “in subsequent years” after “payments” in heading and “(after fiscal year 2013)” after “fiscal year” in text.

Subsec. (f)(3). Puspan. L. 115–52, § 403(f)(2), substituted “2018 through 2022” for “2013 through 2017”.

Subsec. (g). Puspan. L. 115–52, § 403(c)(1), redesignated subsec. (f) as (g). Former subsec. (g) redesignated (h).

Subsec. (h). Puspan. L. 115–52, § 403(c)(2), substituted “subsection (d)” for “subsection (c)”.

Puspan. L. 115–52, § 403(c)(1), redesignated subsec. (g) as (h). Former subsec. (h) redesignated (i).

Subsec. (i). Puspan. L. 115–52, § 403(c)(1), redesignated subsec. (h) as (i).

2016—Subsec. (a)(1)(A)(v). Puspan. L. 114–255, § 3101(a)(2)(V)(i), which directed technical amendment in paragraph (1)(A)(v) to reference in original act which appears in text as reference to July 9, 2012, was executed by making the amendment in introductory provisions and in subcl. (I), to reflect the probable intent of Congress.

Subsec. (a)(2)(B). Puspan. L. 114–255, § 3101(a)(2)(V)(ii), substituted “Biosimilar User Fee Act of 2012” for “Biosimilars User Fee Act of 2012”.

Amendment by Puspan. L. 117–180 effective Oct. 1, 2022, with fees under this subpart to be assessed for all biosimilar biological product applications received on or after Oct. 1, 2022, see section 4006 of Puspan. L. 117–180, set out as a note under section 379j–51 of this title.

Puspan. L. 116–136, div. A, title III, § 3856(span)(2), Mar. 27, 2020, 134 Stat. 458, provided that:

Amendment by section 403 of Puspan. L. 115–52 effective Oct. 1, 2017, with fees under this subpart to be assessed for all biosimilar biological product applications received on or after Oct. 1, 2017, see section 406 of Puspan. L. 115–52, set out as a note under section 379j–51 of this title.

Section ceases to be effective Oct. 1, 2027, see section 4005(a) of Puspan. L. 117–180, set out as a note under section 379j–51 of this title.

Section effective Oct. 1, 2012, with fees under this subpart to be assessed for all biosimilar biological product applications received on or after Oct. 1, 2012, see section 405 of Puspan. L. 112–144, set out as a note under section 379j–51 of this title.